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Abstract
This study was performed to assess the survival times of the Provox™ valve in the Manchester area.
Thirty-nine patients from four hospitals, representing 81 valve failures, were studied. The effects of the
timing of the tracheo-oesophageal puncture, previous radiotherapy, and the presence and timing of
cricopharyngeal myotomy on valve life were analysed. Regression analysis using an extension of the Cox
model to allow strata showed that the lifetime of the first valve only is adversely affected by previous
radiotherapy. The other covariates do not have a statistically significant effect on valve survival. The
median valve survival is 4.5 months, (range one to 12 months). A small percentage of valve users with
particularly frequent valve failures may require additional support and prolonged anti-fungal therapy.
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Introduction
The restoration of speech following total laryngect-
omy is most commonly achieved by the use of
oesophageal speech, an artificial larynx or the
creation of a tracheo-oesophageal fistula and valve
prosthesis (Garth etal., 1991). The valve prosthesis is
generally accepted to be the method of choice in
suitable patients, and allows production of a voice of
superior quality to that achievable by other methods
(Blom et al, 1986; Williams and Watson, 1987;
Pindzola and Cain, 1988; Hilgers and Schouwenburg,
1990). In Manchester, as in other centres, the
Provox™ valve has gained popularity and is now
the most commonly used prosthesis. This paper
describes some aspects of the experience gained over
a period of two years, in 39 patients in whom this
valve was used. We were interested to see whether
differing pre-operative and operative factors influ-
enced valve survival.
Patients and methods
The records of all the 42 laryngectomy patients
using the Provox™ valve at the time of this study
were obtained from five hospitals in the Manchester
area. Variations in treatment patterns enabled a
comparison of valve survival in terms of radio-
therapy and differing surgical techniques in the vocal
rehabilitation of laryngectomy patients. In this study,
valve failure was defined as salivary leakage through
or around the valve, or the inability to effectively
produce a voice using the valve, necessitating valve
replacement. In patients where a functioning valve
was removed at the patient's request, the valve was
not considered to have failed, but the data for that
patient was censored at that time. Three patients
were excluded due to the Provox™ valve being
abandoned within one month of insertion. Two were
changed to Blom Singer valves and one abandoned
due to leakage. The valve failures in the remaining
39 patients were considered in terms of the following
parameters: age, sex; radiotherapy treatment; the
presence and timing of a cricopharyngeal myotomy;
the timing of tracheo-oesophageal puncture and
valve insertion; and the intervals between subse-
quent Provox™ valve replacements. The results were
analysed to see if any changes in practice might
achieve a more effective and economical use of this
prosthesis.
Results
The valve failure time data is not normally
distributed, being positively skewed, with a signifi-
cant number of longer surviving 'outliers'. This is
shown in Figure 1.
Age and sex
The mean age of male patients was 59 years, and
of female patients 56.3 years. Overall the mean age
at laryngectomy was 58.6 years (Range 42-74). The
male to female ratio was 5.5:1.
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FIG. 1
Valve failures in months.
Valve lifetimes
Thirty-nine patients were considered with a total
of 81 valve changes. The analysis of the data was
complicated by two main factors:
a) On valve failure, a further valve was usually
inserted. This process was repeated, up to nine times,
in individual patients. We feel that repeated valve
failures in an individual are likely to be influenced by
factors peculiar to that individual, and cannot be
assumed to be independent of each other.
b) The exact lifetime of the last valve inserted is
often not known, i.e. the valve hasn't failed at the
time of analysis. This is a common feature of analysis
of lifetime data known as censoring.
Statistical methods
A regression approach to analysis of the data was
taken, using an extension of the Cox model to allow
strata (Kalbfleisch and Prentice, 1980; Cox and
Oakes, 1984). This model has a parametric compo-
nent representing the covariates of primary interest
and a non-parametric component for the actual
shape of the underlying lifetime distribution. For the
purposes of analysis the 10 per cent of patients who
underwent secondary myotomy were grouped with
those who had primary myotomy, as they constitute
too small a number to evaluate separately.
We wished to assess first failures separately from
second failures, separately from third failures, etc.
This was achieved by stratifying by failure type (first,
second and third), and using only the data on the first
three failures in any individual. This approach allows
separate quantitative examination of the effects of
the covariates on each of the first three failures, and
a qualitative comparison of the baseline lifetime
distributions.
For failures subsequent to the first failure it is of
interest to examine if the length of previous lifetimes
has any influence on the lifetime of the current valve.
To facilitate this an additional covariate was defined
for the second and third valves as being the average
lifetime of previous valves for that individual.
The mathematical form of the model is included in
appendix 1.
The results showing the parameter estimates and
standard errors from fitting this model are shown in
Table I. It shows that the only effect that is at all
large in relation to its standard error is Zj (the effect
of previous radiotherapy on the first valve lifetime).
To test formally if all the other effects may be
dropped from the model, we may fit a model with Zi
as the sole covariate and use the likelihood ratio test
to compare the two models. This gave a chi-square of
2.90 on 9 degrees of freedom (p = 0.97).
The parameter estimate from the reduced model
was 0.9007 with a standard error of 0.4131. The
effect of this remaining variable was significantly
different from zero (p = 0.03 likelihood-ratio test).
An Arjas plot was constructed and confirmed the
assumption of proportional hazards for Zi (Arjas,
1988).
From the reduced model we have a point estimate
of the relative risk of first valve failure in cases with
previous radiotherapy compared to no previous
radiotherapy of 2.46, with an approximate 95 per
cent confidence interval (1.10, 5.53).
Likelihood ratio tests showed that adding age and
sex variables to the reduced model had no statisti-
cally significant effect (age; p = 0.15 and sex;
p = 0.32). Fom this analysis it appear that the lifetime
of the first valve is affected by previous radiotherapy
but not by cricopharyngeal myotomy or the timing of
the tracheo-oesophageal puncture. Subsequent fail-
ures are not significantly affected by any of these
features nor by the length of previous valve lifetimes.
The results are summarized in Kaplan-Meier plots,
where Figure 2 shows the rate of failure of the first
valve in terms of the presence or absence of previous
radiotherapy, and Figure 3 shows the failure rate of
TABLE I
PARAMETER ESTIMATES AND STANDARD ERRORS OF THIS MODEL
Covariate Variable Estimate
0.9373
-0.3274
-0.1801
0.0919
-0.7242
0.6634
-0.0953
-0.2931
1.2334
0.0136
Standard error
0.4224
0.5639
0.9240
0.4155
0.7056
1.2561
0.4052
0.6264
1.4083
0.0744
Radiotherapy
Cricopharyngeal myotomy
Tracheo-oesophageal puncture
Previous valves
Z2
z3
z4
z5
z6
z7
z8
z9
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the second and third valves (Kaplan and Meier,
1958).
There is a small group of patients (7.7 per cent)
with particularly frequent valve failure. They
account for 24.7 per cent of valve failures. These
patients were more closely scrutinized to see
whether they might have medical conditions such
as chronic bronchitis or gastric-oesophageal reflux
which might possibly adversely affect valve survival.
No particular pattern of conditions was identified in
this sub-group.
Figure 1 shows the distribution of failed valves, in
months. This may reflect bias, as the lifetimes of
valves which are still in situ at the date of censoring
the data are not reflected. These may possibly
survive a longer time, shifting the median of this
distribution. A more accurate picture is derived from
the Kaplan Meier plots in Figures 2 and 3, showing a
median valve survival of 4.5 months (137 days) in
valves subsequent to the first valve, (where radio-
therapy has an influence).
Discussion
This sample of patients reflect the variable
practices of 11 consultants and their junior staff in
four centres in and around Manchester. Of this
sample, 39 per cent had no cricopharyngeal myot-
omy, 51 per cent had primary (at laryngectomy) and
10 per cent secondary (delayed) myotomies. Primary
tracheo-oesophageal puncture was performed in 55
per cent, secondary tracheo-oesophageal puncture in
45 per cent of patients, while 58 per cent had no
previous radiotherapy and 42 per cent previous
radiotherapy. There was no significant difference
between the valve failure rate in the various centres.
The grade of the operating surgeon was not assessed.
All of these patients had a preoperative assess-
ment in conjunction with the respective speech
therapy departments, to assess their suitability for
fitting the Provox™ valve. This included evaluation
of the patients manual dexterity, alcohol intake,
motivation, intelligence, and ability to be instructed
by the speech therapist. The speech therapists
involved with these patients felt that a good quality
voice was produced in over 80 per cent, which is
comparable to other published results (Yoshida et
ai, 1989; Hilgers and Schouwenburg, 1990; Hilgers
and Balm, 1993). This study does not address the
question of the quality of the voice production or
patient satisfaction with the prosthesis, but only the
lifetime of the valve as reflected by the number of
valve changes.
The Provox™ valve has been advocated on the
strengths of allowing effortless, fluent speech
through a low airflow resistant valve, its optimal
self-retaining properties, easy out-patient replace-
ment, and 'long term and predictable device life'
(Hilgers and Schouwenburg, 1990). While agreeing
that the valve allows production of a superior post-
laryngectomy voice, the relative frequency of some
patient's valve changes prompted the authors to
objectively study the valve life in various centres and
assess if this was affected by differing procedures and
pre-operative factors.
Eight of the 39 patients (20.5 per cent), with a
mean follow-up time of six months (range 4-9
months), had not had the Provox™ valve changed
since the initial valve insertion, by the time the data
was censored. The analysis cannot only consider
valves that have failed, as this disregards those valves
in situ at the time of censoring, and may create bias
against the longer-lasting valves. While considering
the quotient of follow-up time and the number of
valve replacements may appear to overcome this
problem, this assumes that- each valve can be
considered a separate entity of equal statistical
weight. In reality however, there must be individual
patient characteristics that influence the valve
survival. For example each valve from one patient
who has had nine valves in two years will be
disproportionately significant compared to those
from a patient with only two valve changes in the
same period, though the frequent changes may be
due to patient factors, such as intractable fungal
infestation or poor valve cleaning. We feel that the
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modified Cox regression analysis considering only
the first three valves in any individual avoids these
pitfalls.
Previous radiotherapy significantly accelerates
failure of the first valve, but not subsequent valves.
We can only speculate that this may be' due to poor
healing of the tracheo-oesophageal fistula in the
tissues compromised by the radiotherapy and that
once the fistula is established, this effect is no longer
a factor. Hilgers and Balm (1993) have reported that
increasing follow-up time has a positive effect on
Provox™ valve survival and that patients with
hypopharyngeal tumours had shorter valve survival.
Interpretation of these results is difficult as mean
valve survivals are quoted from data which are not
normally distributed. Their overall median Provox™
survival quoted of 141 days is comparable to that
shown in our series of 4.5 months (137 days). No
patient had a valve surviving longer than 12 months
in our series.
By far the most common documented cause of
valve failure was leakage of saliva through the
valve or valve blockage, both associated with
Candida sp. infection of the valve. This was almost
always a clinical diagnosis and seldom confirmed by
microbiological means, though this is being eval-
uated by a further study. Candida colonizes the
silicone material causing an increase in airflow
resistance and eventual valve failure with the valve
either blocking or leaking. Amphotericin-B
lozenges decrease candidal colonization and can
significantly increase the life of the prosthesis
(Mahieu et al, 1986; van Lith-Bijl et ai, 1992).
Hilgers and Balm (1993) postulate that radiation
may alter the pharyngeal microbiological environ-
ment and composition of saliva promoting candidal
growth. They advocate anti-fungal preparations on
the cleaning brush used to clean the valve. Possibly,
cleaning of the guide wire with anti-fungal solution
during the process of valve change may improve
valve survival in those patients where there is
obvious candidal presence.
It would seem reasonable to postulate that there
are particular 'patient factors' in the 7.7 per cent of
our patients in whom valve replacement was
particularly frequent, (accounting for 25 per cent of
valve failures). These patients should be identified,
and targeted to improve valve survival. Possibly
those patients in whom valve survival averages less
than three months may benefit from prolonged anti-
fungal therapy, in combination with reassessment of
their competence in* cleaning and maintaining the
valve, with additional support provided by district
nurses or speech therapists. This is the subject of
further study.
In three patients (7.7 per cent), leakage around the
valve necessitated hospitalization, removal of the
valve, and the insertion of a fine-bore naso-gastric
tube to allow the fisula to narrow. This corresponds
to between 10 per cent and 20 per cent of patients in
other series (Hilgers and Schouwenburg, 1990;
Hilgers and Balm, 1993). One patient found that
his oesophageal voice was so effective that he
requested removal of the valve. Other complications
associated with the Provox™ valve included the
formation of granulations around the valve site and
failure in manipulation and use of the valve.
Spontaneous closure of the tracheo-oesophageal
fistula was unfortunately not the rule in patients
who had their valves removed, and surgical closure
was required in three cases (7.7 per cent).
Difficulties in changing the valve were not always
well documented in the patient's notes, but occurred
in a number of patients known to the authors. There
was no case of the valve being dislodged into the
oesophagus, but in two patients, valve failure was
complicated by healing of the oesophageal mucosa,
closing the fistula. When the guide wire was inserted
through the apparently in situ valve this resulted in
the creation of a false passage. The guide wire was
withdrawn when it did not appear in the pharynx and
was found to be blood-stained. Complete healing of
the oesophageal mucosa was confirmed by endo-
scopy and a repeat puncture was required. It is
tempting to speculate that this complication occurred
because of an inappropriate selection of valve size
for the thickness of the tracheo-oesophageal party
wall, but in neither patient was this the first valve
used, and in both patients the same sized valve (size
8) was subsequently used successfully.
A pharyngeal stricture tends to make changing the
valve difficult and in some patients valve changing
routinely requires endoscopy and pharyngeal dilata-
tion under a general anaesthetic.
There is no evidence from our data that the
presence of a cricopharyngeal myotomy or the
timing of the tracheo-oesophageal puncture influ-
ence valve survival. This does not exclude the
possibility that when larger samples are analysed,
these factors may be significant.
Only 51 per cent of this sample had a primary
cricopharyngeal myotomy. While this was not shown
to have a statistically significant effect on valve
survival, there are arguments in favour of routine
primary myotomy. An adequate myotomy certainly
favourably contributes to voice production by both
oesophageal and tracheo-oesophageal speech
(Singer and Blom, 1981; Wenig et al., 1989; van
Weissenbruch and Albers, 1992; Duguay and Feudo,
1988). Although primary myotomy may produce a
hypotonic pharyngo-oesophageal (PE) segment in
up to 10 per cent of cases, this can be overcome by
pressure applied by the patient's hand, to the neck
above the fistula, to narrow the P-E segment during
speech (Garth et ai, 1991). This complication should
be weighed up against the technical difficulties and
morbidity of further surgery. Twenty-two per cent of
our patients who did not have a primary myotomy,
(10 per cent of the total sample), had a secondary
myotomy following the demonstration of a hyper-
tonic PE segment on Taub testing(or because of
poor., voice production with a valve in situ. Phar-
yngeal neurectomy has been proposed as an alter-
native to cricopharyngeal myotomy but this
technique has not gained wide acceptance in Britain
(Taub and Bergner, 1973; Singer et al., 1986).
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Of our patients, 55 per cent had primary tracheo-
oesophageal puncture and valve insertion. This did not
appear to affect valve survival. The advantages of
primary valve insertion include earlier development of
adequate speech and the avoidance of a second surgical
episode. We also feel that the creation of the fistula and
valve insertion under direct vision is technically easier
than as a secondary procedure. Those advocates of
delayed valve insertion argue that the valve may
promote stomal infection and even mediastinitis,
which could substantially prolong the hospital stay.
These complications were not evident in the primary
valve insertion patients in this series, and there does not
appear to be a statistically significant difference
between the complication rates in the two approaches
in the literature (Trudeau et ai, 1986; Maniglia et ai,
1989; van Weissenbruch and Albers, 1992). A propor-
tion of our patients who had secondary valve insertion
represent those patients who had their laryngectomies
before the widespread use of valves for speech
rehabilitation, and primary valve insertion is increas-
ingly the trend.
Conclusions
Previous radiotherapy is likely to adversely affect
the life span of the first, but not subsequent valves.
The life span of subsequent Provox™ valves, has a
distribution median of 4.5 months. There is a small
group of patients with particularly rapid valve
turnover. These are not identified by pre-operative
or operative factors in this study. For economic and
logistical reasons, these patients should be identified,
(at present empirically), and their ability to maintain
the valve reassessed. A long-term course of anti-
fungal therapy and additional support from speech
therapists or district nurses may be required.
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Appendix
Modified Cox Regression Analysis
The mathematical form of the model was as follows:
\ij(t) = \oj(t)e(p1Ziij +p2Z2ij + PioZloij)
where i indexes individuals (i = 1,2, . . . , 39)
and j indexes the valve (j = 1,2,3)
\jj(t) is the conditional failure rate for the j t h valve,
on the ith individual, at time t from the insertion of
the valve.
XOj(t) is the baseline conditional failure rate for the
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j t h valve (The actual form of this function is left
unspecified).
Type-specific covariates were defined to allow for
differing effects of the baseline covariates on each
valve failure as follows:
Ziij = 0 j # 1 or j = l and RT = no
= 1 j = 1 and RT = yes
Radiotherapy Zzij = 0 j # 2 or j=2 and RT = no
(RT) = 1 . - j=2andRT = yes
Z3ij =0 j * 3 or j=3 and RT = no
= 1 or j=3 and RT = yes
Thus Z!_3 represents valve changes 1-3, with or
without radiotherapy. Similarly, covariates were
denned as cricopharyngeal myotomy ( Z ^ repre-
senting valve changes 1-3 with or without cricophar-
yngeal myotomy), and primary and delayed tracheo-
oesophageal puncture (where Z7_9 represent valve
changes 1-3 with respect to this variable). Previous
valve lifetime was defined as:
Z10ij = 0 j = 1
Zioij = (average lifetime previous valves)/28 j = 2,3
The results are shown in Table 1 and Figures 2 and 3.
